Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

October 11, 2021

Study Completion Date

March 1, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Elotuzumab

Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15

DRUG

Carfilzomib

Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond

DRUG

Lenalidomide

Lenalidomide will be given on days 1-21 for all cycles.

DRUG

Dexamethasone

"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"

Trial Locations (3)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

60201

NorthShore University Health System, Evanston

60637

University of Chicago, Chicago

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Amgen

INDUSTRY

collaborator

Multiple Myeloma Research Foundation

OTHER

lead

University of Chicago

OTHER

NCT02969837 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | Biotech Hunter | Biotech Hunter